Beyond Air, Inc. (NASDAQ:XAIR) Short Interest Update

Beyond Air, Inc. (NASDAQ:XAIR) saw a large growth in short interest in February. As of February 28th, there was short interest totalling 1,530,000 shares, a growth of 27.5% from the February 13th total of 1,200,000 shares. Based on an average daily trading volume, of 1,550,000 shares, the short-interest ratio is presently 1.0 days. Approximately 2.8% of the shares of the stock are sold short.

Institutional Investors Weigh In On Beyond Air

Institutional investors and hedge funds have recently modified their holdings of the business. Soros Fund Management LLC bought a new position in shares of Beyond Air in the 3rd quarter valued at approximately $573,000. Baldwin Wealth Partners LLC MA raised its position in shares of Beyond Air by 721.3% in the fourth quarter. Baldwin Wealth Partners LLC MA now owns 308,000 shares of the company’s stock valued at $110,000 after purchasing an additional 270,500 shares during the period. Squarepoint Ops LLC acquired a new stake in shares of Beyond Air in the fourth quarter worth $48,000. Wealthedge Investment Advisors LLC bought a new stake in shares of Beyond Air during the 4th quarter worth $80,000. Finally, Balyasny Asset Management L.P. acquired a new position in Beyond Air in the 4th quarter valued at $1,195,000. Institutional investors and hedge funds own 31.50% of the company’s stock.

Beyond Air Stock Up 7.2 %

Shares of XAIR stock opened at $0.27 on Monday. Beyond Air has a fifty-two week low of $0.24 and a fifty-two week high of $1.78. The stock has a 50-day simple moving average of $0.35 and a 200 day simple moving average of $0.41. The stock has a market capitalization of $18.48 million, a P/E ratio of -0.25 and a beta of 0.16.

Beyond Air (NASDAQ:XAIR) last posted its quarterly earnings results on Monday, February 10th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.09. Beyond Air had a negative return on equity of 226.01% and a negative net margin of 1,730.00%. During the same quarter last year, the business earned ($0.50) EPS. On average, sell-side analysts anticipate that Beyond Air will post -0.79 earnings per share for the current year.

Beyond Air Company Profile

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.